Given the central role of HIF-1 in the activation of numerous pathways responsible for tumorigenesis and progression of HCC, it is not surprising that targeting HIF-1 has become a novel therapeutic strategy. This evidence concerns the gene HIF1A and hepatocellular carcinoma.